<DOC>
	<DOCNO>NCT01793298</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability dry powder formulation ASM-024 follow single multiple administration inhalation ascend dos healthy subject subject stable moderate asthma .</brief_summary>
	<brief_title>Safety , Tolerability Pharmacokinetics ASM-024 Administered Healthy Subjects Subjects With Moderate Asthma</brief_title>
	<detailed_description>This phase I/II , randomize , double-blind , placebo-controlled study single ascend multiple ascend dos ASM-024 administer dry powder inhalation healthy subject subject stable moderate asthma . The goal study evaluate safety , tolerability pharmacokinetic profile new , dry powder formulation ASM-024 . The dos test subject asthma determine base information collect first healthy volunteer . In addition standard safety tolerability evaluation , acute effect study medication airway assess .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<criteria>Healthy Volunteers : Healthy male female adult , 18 55 year age ; nonsmoker former smoker ; Normal lung function ; Normal 12lead ECG Asthmatics : Male female adult , 18 60 year age diagnosis moderate asthma accord GINA Guidelines regular inhale corticosteroid without short longacting beta 2agonists ; Nonsmoker former smoker ; FEV1 ≥ 70 % predict absence medication asthma ; Baseline methacholine PC20 ≤ 16 mg/mL ; Normal 12lead ECG . Healthy Volunteers : Clinically significant illness surgery within 8 week prior first administration study medication ; Significant medical history , Investigator 's opinion , may adversely affect participation ; History allergy significant adverse reaction drug similar ASM024 , nicotine , cholinergic drug drug similar chemical structure ; History hypersensitivity ( anaphylaxis , angioedema ) drug ; Use drug know induce inhibit hepatic drug metabolism , within 30 day prior first administration study medication ; Positive pregnancy test female subject ; Use medication know prolong QT/QTc interval within 14 day prior first administration study medication ; Clinically significant 12 lead ECG abnormality Screening ; ; Clinically significant physical examination laboratory finding Screening ; History alcohol drug abuse ; Tobacco use within 12 month prior Screening , nicotinecontaining product within 6 month prior Screening . History smoking must ≤ 10 packyears ; Positive hepatitis B C HIV test Screening ; Investigational drug within 30 day prior first administration study medication , longacting investigational drug within 90 day prior first administration study medication ; Previous exposure ASM024 ; Women childbearing potential male participant unwilling unable use accept method birth control . Asthmatics : Clinically significant illness surgery within 8 week prior first administration study medication ; Significant medical history , Investigator 's opinion , may adversely affect participation ; History allergy significant adverse reaction drug similar ASM024 , nicotine , cholinergic drug drug similar chemical structure ; History hypersensitivity ( anaphylaxis , angioedema ) drug ; Use drug know induce inhibit hepatic drug metabolism , within 30 day prior first administration study medication ; Positive pregnancy test female subject ; Use medication know prolong QT/QTc interval ; Clinically significant 12 lead ECG Screening ; Clinically significant physical examination laboratory finding abnormal vital sign ; Baseline methacholine PC20 &gt; 16 mg/mL Screening ; History illicit drug use alcohol abuse within 12 month Screening ; Tobacco use within 12 month prior Screening , nicotinecontaining product within 6 month prior Screening . History smoking must ≤ 10 packyears ; Positive hepatitis B C HIV test Screening ; Any follow concomitant medication precede administration methacholine Screening precede administration study medication Visit 1 : ( ) oral i.v . corticosteroid within 1 month ; ( ii ) inhale intranasal corticosteroid within 48 hour ; ( iii ) longacting beta2agonists within 48 hour ; ( iv ) shortacting beta2agonists within 8 hour ; ( v ) anticholinergic aerosol within 24 hour ; ( vi ) theophylinecontaining product within 48 hour ; ( vii ) NSAIDs within 7 day precede administration methacholine Screening throughout study ; ( viii ) antihistaminic drug within 3 day ; Investigational drug within 30 day Screening ; longacting investigational drug within 90 day Screening ; Previous exposure ASM024 ; Women childbearing potential male participant unwilling unable use accept method birth control .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>